3 Promising Penny Stocks With Market Caps Over $100M

Major stock indexes in the United States recently ended a mixed session, with the Dow Jones Industrial Average closing at a record high amid a flurry of corporate earnings reports. For investors seeking opportunities beyond the blue-chip stocks, penny stocks—despite their somewhat outdated name—remain an intriguing area for potential growth. These smaller or newer companies can offer significant value when they are built on solid financial foundations, and we've identified three such penny stocks that combine balance sheet strength with potential upside.

Top 10 Penny Stocks In The United States

Click here to see the full list of 363 stocks from our US Penny Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Commerce.com (CMRC)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Commerce.com, Inc. provides a software-as-a-service e-commerce platform for brands and retailers across multiple regions worldwide, with a market cap of $391.57 million.

Operations: The company's revenue is primarily derived from its Internet Information Providers segment, totaling $337.54 million.

Market Cap: $391.57M

Commerce.com, Inc., with a market cap of US$391.57 million, operates in the e-commerce sector and is currently unprofitable, though it has reduced losses over five years by 5.8% annually. The company's short-term assets exceed both its short and long-term liabilities, indicating solid financial management despite a high net debt to equity ratio of 59.6%. Recent strategic initiatives include launching BigCommerce Payments with PayPal for enhanced payment solutions and Feedonomics Surface to optimize advertising data feeds. These developments aim to bolster operational efficiency and expand market reach across diverse channels while maintaining a stable cash runway exceeding three years.

• Take a closer look at Commerce.com's potential here in our financial health report.
• Assess Commerce.com's future earnings estimates with our detailed growth reports.

MacroGenics (MGNX)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing antibody-based cancer therapeutics in the United States with a market cap of approximately $127.68 million.

Operations: The company generates revenue of $165.50 million from its efforts in developing and commercializing monoclonal antibody-based therapeutics.

Market Cap: $127.68M

MacroGenics, Inc., with a market cap of US$127.68 million, is navigating the challenges typical of penny stocks in the biotech sector. Despite being unprofitable, it has improved its financial position by reducing losses annually by 26% over five years and maintaining a cash runway exceeding one year. The company's recent revenue growth to US$22.24 million for Q2 2025, up from US$10.8 million a year ago, highlights progress despite ongoing net losses. Leadership changes include Eric Risser's appointment as CEO, bringing extensive experience from his tenure at MacroGenics and previous roles at Johnson & Johnson.

• Get an in-depth perspective on MacroGenics' performance by reading our balance sheet health report here.
• Review our growth performance report to gain insights into MacroGenics' future.

Taboola.com (TBLA)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Taboola.com Ltd. operates an artificial intelligence-based algorithmic engine platform across Israel, the United States, the United Kingdom, Germany, and internationally with a market cap of approximately $922.14 million.

Operations: The company's revenue is primarily generated from its advertising segment, which totaled $1.82 billion.

Market Cap: $922.14M

Taboola.com Ltd., with a market cap of US$922.14 million, has shown resilience as it transitions to profitability. Recent partnerships, like the one with India Today Group for its DeeperDive AI engine, highlight its innovative approach in the digital advertising space. Despite a net loss of US$4.35 million in Q2 2025, revenues increased to US$465.47 million from the previous year, and earnings are forecasted to grow significantly at 28% annually. The company maintains strong financial health with short-term assets exceeding liabilities and debt well-covered by operating cash flow, supporting its strategic growth initiatives in AI-driven content monetization.

• Click here and access our complete financial health analysis report to understand the dynamics of Taboola.com.
• Explore Taboola.com's analyst forecasts in our growth report.

Seize The Opportunity

• Take a closer look at our US Penny Stocks list of 363 companies by clicking here.
• Seeking Other Investments? Uncover 12 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com